Enorama Pharma AB (publ)

OM:ERMA Stock Report

Market Cap: SEK 199.0m

Enorama Pharma Past Earnings Performance

Past criteria checks 0/6

Enorama Pharma's earnings have been declining at an average annual rate of -14.6%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been declining at an average rate of 10.4% per year.

Key information

-14.6%

Earnings growth rate

17.1%

EPS growth rate

Pharmaceuticals Industry Growth30.5%
Revenue growth rate-10.4%
Return on equity-105.4%
Net Margin-267.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Enorama Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OM:ERMA Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2413-36320
30 Jun 246-41340
31 Mar 241-42340
31 Dec 231-45340
30 Sep 231-44360
30 Jun 235-39330
31 Mar 237-41360
31 Dec 227-42380
30 Sep 2211-37340
30 Jun 229-38370
31 Mar 2210-33330
31 Dec 2113-28300
30 Sep 2110-28330
30 Jun 218-25280
31 Mar 216-24250
31 Dec 204-23250
30 Sep 205-22220
30 Jun 207-25240
31 Mar 2010-25250
31 Dec 1910-24240
30 Sep 1911-23110
30 Jun 1911-1980
31 Mar 199-1870
31 Dec 1812-1660
30 Sep 1811-13100
30 Jun 1810-1180
31 Mar 1810-1060
31 Dec 175-930
30 Sep 173-810
30 Jun 175-600
31 Mar 173-820
31 Dec 164-820
30 Sep 166-580
30 Jun 164-470
31 Mar 163-140
31 Dec 152-130
31 Dec 141010

Quality Earnings: ERMA is currently unprofitable.

Growing Profit Margin: ERMA is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ERMA is unprofitable, and losses have increased over the past 5 years at a rate of 14.6% per year.

Accelerating Growth: Unable to compare ERMA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ERMA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9.5%).


Return on Equity

High ROE: ERMA has a negative Return on Equity (-105.43%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 12:37
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Enorama Pharma AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution